307 related articles for article (PubMed ID: 9322828)
1. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril.
Black HR; Graff A; Shute D; Stoltz R; Ruff D; Levine J; Shi Y; Mallows S
J Hum Hypertens; 1997 Aug; 11(8):483-9. PubMed ID: 9322828
[TBL] [Abstract][Full Text] [Related]
2. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study.
Malacco E; Santonastaso M; Varì NA; Gargiulo A; Spagnuolo V; Bertocchi F; Palatini P;
Clin Ther; 2004 Jun; 26(6):855-65. PubMed ID: 15262456
[TBL] [Abstract][Full Text] [Related]
3. Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension.
Bremner AD; Baur M; Oddou-Stock P; Bodin F
Clin Exp Hypertens; 1997 Nov; 19(8):1263-85. PubMed ID: 9385475
[TBL] [Abstract][Full Text] [Related]
4. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril.
Holwerda NJ; Fogari R; Angeli P; Porcellati C; Hereng C; Oddou-Stock P; Heath R; Bodin F
J Hypertens; 1996 Sep; 14(9):1147-51. PubMed ID: 8986917
[TBL] [Abstract][Full Text] [Related]
5. Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study.
Fogari R; Zoppi A; Carretta R; Veglio F; Salvetti A;
J Hypertens; 2002 May; 20(5):1007-14. PubMed ID: 12011663
[TBL] [Abstract][Full Text] [Related]
6. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide.
Benz J; Oshrain C; Henry D; Avery C; Chiang YT; Gatlin M
J Clin Pharmacol; 1997 Feb; 37(2):101-7. PubMed ID: 9055135
[TBL] [Abstract][Full Text] [Related]
7. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
[TBL] [Abstract][Full Text] [Related]
8. Dose-response efficacy of valsartan, a new angiotensin II receptor blocker.
Pool JL; Glazer R; Chiang YT; Gatlin M
J Hum Hypertens; 1999 Apr; 13(4):275-81. PubMed ID: 10333347
[TBL] [Abstract][Full Text] [Related]
9. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF
J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
[TBL] [Abstract][Full Text] [Related]
10. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
[TBL] [Abstract][Full Text] [Related]
11. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy.
Benz JR; Black HR; Graff A; Reed A; Fitzsimmons S; Shi Y
J Hum Hypertens; 1998 Dec; 12(12):861-6. PubMed ID: 9883710
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension.
Oparil S; Dyke S; Harris F; Kief J; James D; Hester A; Fitzsimmons S
Clin Ther; 1996; 18(5):797-810. PubMed ID: 8930424
[TBL] [Abstract][Full Text] [Related]
14. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
Baruch L; Anand I; Cohen IS; Ziesche S; Judd D; Cohn JN
Circulation; 1999 May; 99(20):2658-64. PubMed ID: 10338459
[TBL] [Abstract][Full Text] [Related]
15. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.
Corea L; Cardoni O; Fogari R; Innocenti P; Porcellati C; Provvidenza M; Meilenbrock S; Sullivan J; Bodin F
Clin Pharmacol Ther; 1996 Sep; 60(3):341-6. PubMed ID: 8841157
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.
Oparil S; Yarows SA; Patel S; Fang H; Zhang J; Satlin A
Lancet; 2007 Jul; 370(9583):221-229. PubMed ID: 17658393
[TBL] [Abstract][Full Text] [Related]
17. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
[TBL] [Abstract][Full Text] [Related]
18. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial.
Elliott WJ; Calhoun DA; DeLucca PT; Gazdick LP; Kerns DE; Zeldin RK
Clin Ther; 2001 Aug; 23(8):1166-79. PubMed ID: 11558856
[TBL] [Abstract][Full Text] [Related]
19. Sustained antihypertensive activity of telmisartan compared with valsartan.
Lacourcière Y; Krzesinski JM; White WB; Davidai G; Schumacher H
Blood Press Monit; 2004 Aug; 9(4):203-10. PubMed ID: 15311147
[TBL] [Abstract][Full Text] [Related]
20. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide.
Hegner G; Faust G; Freytag F; Meilenbrock S; Sullivan J; Bodin F
Eur J Clin Pharmacol; 1997; 52(3):173-7. PubMed ID: 9218922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
